RenaSci

Perifused Pancreatic Islets

Perifused Pancreatic Islets

 

In mammals, the peptide hormone insulin, stimulates glucose uptake by the liver, muscle and adipose tissue and therefore plays a primary role in maintaining blood glucose homeostasis. Insulin is synthesized in the pancreas within the ß-cells of the islets of Langerhans and is secreted in response to various circulating factors including raised blood glucose levels.

Type 2 diabetes results from insulin resistance, due to impaired insulin signalling and action. The initial response of the body to insulin resistance is to secrete more insulin. However, as the insulin resistance worsens, pancreatic ß-cells fail to secrete sufficient insulin to overcome the insulin resistance, and type 2 diabetes results.

Isolated perifused pancreatic islets can be used to determine whether potential antidiabetic agents alter insulin secretion from ß-cells in vitro. The perifused pancreatic islet assay established and validated by RenaSci can therefore be employed as an invaluable tool in any type 2 diabetes drug discovery programme.

Key features of the perifused pancreatic islet assay include :-

     •     Direct measurement of perifused pancreatic islet insulin secretion in vitro
     •     Detailed mechanistic studies or medium-throughput screening
     •     Methodology validated using islets from normal (Sprague Dawley and Wistar) and 
           Zucker fatty fa/fa rats - other models considered

All perifused pancreatic islet studies are customised to meet the specific requirements of each client and include advice on experimental design, statistical analysis by a qualified statistician, fully audited data pack and written reports to regulatory standards if required.

 

Glucose-Stimulated Insulin Secretion from Perifused Pancreatic Islets

 

GLP-1 Increases Glucose-Stimulated Insulin Secretion from Perifused Pancreatic Islets

 

Please contact us for further information about our perifused pancreatic islet assay. 


Posters

 
Lynch et al. 2011. Potential role of direct K-ATP channel opening in the anti-diabetic actions of rimonabant and ibipinabant. Abstract No. 2011-P. American Diabetes Association 71st Scientific Sessions, San Diego, California, USA, 24th-28th June 2011.

 
Manuscripts

Lynch et al. 2012. Some cannabinoid receptor ligands and their distomers are direct acting openers of SUR1 KATP channels. Am J Physiol Endocrinol Metab 302(5): E540-E551. [PubMed]

.